Skip to main content
. 2018 Jan 11;9(44):27574–27584. doi: 10.18632/oncotarget.24164

Figure 1. Analysis of the expression and prognosis value of CD300A, PECAM1 and ADCY7 in human acute myeloid leukemia.

Figure 1

(A–C) The mRNA expression of CD300A, PECAM1, and ADCY7, were all significantly higher compared to the normal sample. (D–F) Representing CD300A, PECAM1, and ADCY7, showed coexpression in AML. In graphs (G–I) low mRNA expression of CD300A was correlated with a better prognosis in AML, as well as PECAM1 and ADCY7. In conclusion, these results suggest that CD300A, PECAM1, and ADCY7 have functional relevance and potential biological functions in AML.